Drafting Consumer Breach Notices — From a Litigation Perspective - Unauthorized Access Podcast
Landlord and Tenant Lease Risk Reduction for the Cannabis Industry
Insurtech Briefly Podcast: Licensing, Google and Lead Gens
Edible Bites Episode 7: Oregon Psilocybin Services Act, Measure 109 Overview and Licensure
PODCAST: GovCon Perspectives - Are You Interested in Investing in a Company With a Federal Firearms License (FFL)?
Bill on Bankruptcy: Supreme Court Cases Will Have Wide Impact
Polsinelli Podcast - Avoiding Professional Liability
Patent Series: Protecting inventions
License to travel: how regulation is benefiting business abroad
Uncertainty Surrounds Illinois’s Nationally-Watched Collaborative Legislation On Fracking
Harlem Shake's Copyright Issues
Craft Beer Boom in Michigan
Unlocking Your Cell Phone Is Now Illegal, but Not for Long
Weekly Brief: New DOJ Tact Pushes Bank Subsidiaries To Admit Guilt
Looking Ahead to Washington State’s Legalized Marijuana Marketplace
Key Takeaways: The draft guidance represents the first-ever specific expectation by FDA that sponsors develop a diversity plan for trials. FDA’s recommendations come as part of increasing interest in ensuring clinical...more
The Food and Drug Administration (FDA) released new draft guidance, Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act, intended for prospective applicants of biologics...more
The FDA recently requested comment on its draft guidance for implementation of the “deemed to be a license” provision as described in section 7002(e) of the Biologics Price Competition and Innovation Act of 2009 (“BPCI Act”)....more